Giuseppe
Emeritus
[Source: Eurosurveillance, full text: (LINK). Extract, edited.]
Eurosurveillance, Volume 16, Issue 48, 01 December 2011
Editorials
Treatment as prevention: will it work?
M J van de Laar (
)<SUP>1</SUP>, A Pharris<SUP>1</SUP>
Citation style for this article: van de Laar MJ, Pharris A. Treatment as prevention: will it work?. Euro Surveill. 2011;16(48)
ii=20029. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20029
Date of submission: 30 November 2011 <HR>
In the past two years, rapidly emerging new trial results have provided the scientific community and people living with human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS) or at risk of infection, with welcome news. Interesting scientific evidence is accumulating for the effectiveness of biomedical interventions to prevent the transmission of HIV. Infected people may become less contagious when the viral load is suppressed by antiretroviral therapy (ART). In 2010, results from the Pre-Exposure Prophylaxis Initiative (iPreX) randomised controlled trial provided the first evidence that antiretroviral pre-exposure prophylaxis can reduce HIV incidence. In their study, Grant et al showed, that that daily oral antiretroviral medication reduced HIV incidence in HIV negative men who have sex with men (MSM) by 44% [1]. In July 2011, two studies from the United States, the TDF2 (tenofovir disoproxil fumarate and emtricitabine (TDF)) study and the Partners Pre-exposure study provided evidence that a daily oral dose of antiretroviral medication can reduce HIV acquisition among uninfected individuals exposed to the virus through heterosexual sex by at least 60% [2-3]. The randomised controlled HIV Prevention Trials Network study (HPTN 052) by Cohen et al demonstrated that earlier treatment (time of enrolment in study compared with CD4 cell counts within or below 200-250 cells/mm3 or developing an AIDS defining illness) of HIV-infected persons with ART had both a clinical benefit for the infected individual and resulted in a 96% reduction in transmission to the uninfected sexual partner [4].
(?)
- -----
Eurosurveillance, Volume 16, Issue 48, 01 December 2011
Editorials
Treatment as prevention: will it work?
M J van de Laar (
- European Centre for Disease Prevention and Control, Stockholm, Sweden ECDC, Stockholm
Citation style for this article: van de Laar MJ, Pharris A. Treatment as prevention: will it work?. Euro Surveill. 2011;16(48)
ii=20029. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20029 Date of submission: 30 November 2011 <HR>
In the past two years, rapidly emerging new trial results have provided the scientific community and people living with human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS) or at risk of infection, with welcome news. Interesting scientific evidence is accumulating for the effectiveness of biomedical interventions to prevent the transmission of HIV. Infected people may become less contagious when the viral load is suppressed by antiretroviral therapy (ART). In 2010, results from the Pre-Exposure Prophylaxis Initiative (iPreX) randomised controlled trial provided the first evidence that antiretroviral pre-exposure prophylaxis can reduce HIV incidence. In their study, Grant et al showed, that that daily oral antiretroviral medication reduced HIV incidence in HIV negative men who have sex with men (MSM) by 44% [1]. In July 2011, two studies from the United States, the TDF2 (tenofovir disoproxil fumarate and emtricitabine (TDF)) study and the Partners Pre-exposure study provided evidence that a daily oral dose of antiretroviral medication can reduce HIV acquisition among uninfected individuals exposed to the virus through heterosexual sex by at least 60% [2-3]. The randomised controlled HIV Prevention Trials Network study (HPTN 052) by Cohen et al demonstrated that earlier treatment (time of enrolment in study compared with CD4 cell counts within or below 200-250 cells/mm3 or developing an AIDS defining illness) of HIV-infected persons with ART had both a clinical benefit for the infected individual and resulted in a 96% reduction in transmission to the uninfected sexual partner [4].
(?)